Linearis receives a contribution from the Government of Canada to support the $7M modernization of its metabolomics platform, integrating artificial intelligence

Québec City, June 3rd 2025 – Linearis Labs receives a $1M loan from Canada Economic Development for the Quebec Regions (CED) for the first phase of the modernization of its metabolomics platform, a $7M project also supported by the City of Quebec.

“Linearis recently inaugurated Canada’s first commercial high-throughput metabolomics laboratory integrating artificial intelligence (AI) in Canada. With CED’s support, this new state-of-the-art facility will open up new perspectives on the diagnosis and treatment of several medical conditions.’’ highlights the Honourable Joël Lightbound, Member of Parliament for Louis-Hébert and Minister of Government Transformation, Public Works and Procurement. “This initiative consolidates Linearis’s leadership in the medical industry and propels innovation forward, thereby contributing to a stronger Canadian economy.’’

By combining cutting-edge equipment with metabolomic expertise, Linearis’ laboratory collaborates with several life sciences players, including the Canadian Biomedical Research Fund (CBRF) and the Biosciences Research Infrastructure Fund (BRIF), to prepare Canada for future health crises and pandemics.

“Academic researchers, clinical research organizations and BioPharma companies will gain enhanced capabilities to assess drug toxicity and compile efficacy profiles, seamlessly integrating these insights to accelerate their discovery and validation processes. We take pride in providing world-class expertise, supporting life sciences innovators across Canada and on the global stage,” said Alexandre Le Bouthillier, PhD, CEO of Linearis.

About CED 

CED’s mission is to promote the long-term economic development of Quebec’s regions, with special attention to those with slow economic growth or inadequate opportunities for productive employment.

About Linearis

Linearis, through its tandem ventures fund and laboratory, pioneers and supports discoveries to prevent, detect, and treat metabolic diseases, including cancer and diabetes, through direct investment in innovative AI and life science companies.

Media Contact

Manon Boisclair, MS, MBA, ICD.D
Linearis- General Partner & COO

media@linearis.com